Aachen, May 7th 2014 – Grünenthal Group today announced the signing of an exclusive promotion and distribution agreement with MSD covering etoricoxib. This agreement covers Germany, UK, France, Belgium, Luxemburg, Ireland, and Austria. Etoricoxib is a patent-protected, selective COX-2 inhibitor, marketed under the brand name Arcoxia® in these markets.
“Arcoxia® is a valuable addition to Grünenthal’s product portfolio and strongly contributes to further strengthening our position as a leading player in pain therapy. By including Arcoxia® into our portfolio in select countries, Grünenthal now also offers an innovative therapy option for the treatment of pain with an inflammatory component, which therefore complements our other existing therapy options for the treatment of nociceptive and mixed nociceptive-neuropathic pain,” said Dott. Alberto Grua, Chief Commercial Officer Europe, Australia and North America of Grünenthal-Group.
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation. Grünenthal is one of the last five remaining research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. Research and development costs amounted to about 27 percent of revenues in 2013. Grünenthal’s research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies. Altogether, the Grünenthal Group has affiliates in 25 countries worldwide. Grünenthal products are sold in more than 155 countries. Today, approx. 4,400 employees are working for the Grünenthal Group worldwide. In 2013, Grünenthal achieved revenues of €901 mn.
More information: www.grunenthal.com.
Vice President Public Engagement
Phone +49 241 569-1568